

INTERIM FORMULARY UPDATE

The following recommendations, made at the September 25, 2009 meeting of the Executive Formulary Committee, are approved:

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:

| Generic Name | Brand Name | Dosage Form | Classification |
|------------------------|--|--|--|
| Cycloserine | Seromycin [®] | Capsule: 250 mg | Infectious Disease Agents; Antibiotic; Miscellaneous (Reserve) |
| Paliperidone palmitate | Invega [®] Sustenna [™] | Injection, Long-Acting: 39 mg, 78 mg, 117 mg, 156 mg, 234 mg | Psychotropic Agents; Antipsychotic |
| Epoetin alfa | Epogen [®] , Procrit [®] | Injection: 2,000 Units/ml, 3,000 Units/ml, 4,000 Units/ml, 10,000 Units/ml, 20,000 Units/ml, 40,000 Units/ml | Blood Modifying Agents; Miscellaneous (Reserve) |

Product(s) **recommended to be added** to the DADS/DSHS Drug Formulary based on the Sectional Review for Agents for Migraine:

| Generic Name | Brand Name | Dosage Form | Classification |
|--|-----------------------|--------------------|---------------------|
| Aspirin/ Acetaminophen/ caffeine | Excedrin [®] | Tablet: 250/250/65 | Agents for Migraine |

Dosage strength(s) **added** to the DADS/DSHS Drug Formulary based on an additional review of the Formulary:

- Brimonidine
 - Solution, ophthalmic: 0.1%
- Trizanidine
 - Capsule: 2 mg, 4 mg.
- Calcipotriene
 - Solution, topical: 0.005%
- Donepezil
 - Tablet, oral disintegrating: 10 mg

Approved: *Ann F. Richards*

Ann Richards, Pharm.D. BCPP
Pharmacy Services Director, San Antonio State Hospital

10-22-09

Date: